Table 2 Comparison of the therapeutic effects of DBS in patients carrying VPD35 p.D620N mutation and sporadic PD
Reference | VPD35 p.D620N mutation carriers | Age of onset (mean ± SD, years) | Age at receiving DBS (mean ± SD, years) | DBS stimulation details that gained the best clinical response | LEDD before DBS (mg) | LEDD one year after DBS (mg) | Improvement of UPDRS motor scores one year after DBS in “OFF” medications | LEDD five to eight years after DBS (mg) |
|---|---|---|---|---|---|---|---|---|
Fleury V et al., 2013 [14] | + (patient 1) | 49 | 60 | Monopolar stimulation of two most proximal contacts (3-) at 2.2 V in the right STN and 2.4 V in the left STN, with a frequency of 130 Hz and pulse duration of 60 ms. | 1540 | 400 | 76% | 550 (eight years after DBS) |
+ (patient 2) | 45 | 55 | Monopolar stimulation of the 3rd and 4th distal contact (2–3-) in the right STN at 3.3 V and 3.0 V in the left STN, with a frequency of 180 Hz and pulse duration of 90 ms. | 1276.5 | 300 | 36% | N.A. | |
Current study | + (index patient) | 42 | 55 | Monopolar stimulation of the two dorsal contacts (6−/2-) at 4.4 V in the right STN and 3.2 V in the left STN, with a frequency of 160 Hz and pulse duration of 90 ms in the right STN and 60 ms in the left STN | 1435 | 1000 | 37% | 1160 (five years after DBS) |
Aviles-Olmos I et al., 2014 [16] | - 41 sporadic PD patients | 43.3 ± 9.8 | 56.2 ± 8.4 | Monopolar stimulation | 1471 ± 515 | 949 ± 572 | 45.5 ± 12.8% | 668 ± 359 (five years after DBS) |